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The Human Immunodeficiency Virus (HIV) coreceptor
switch, which entails the change in preferential coreceptor
usage of the virus for CCR5 to CXCR4 in ~50% of all HIV
subtype B infected patients, is an important determinant
in the pathogenesis of HIV infection. However, the mech-
anisms underlying this switch are poorly understood, and
prognostic markers for this switch are unknown. Here, we
describe the upregulation of the novel adipocytokine vis-
fatin (NAMPT) in monocytes of therapy-naïve HIV
patients, which is reversed during antiretroviral therapy.
Induction of visfatin was observed both at the mRNA and
protein level and was mirrored by an increase in plasma
visfatin in therapy-naïve HIV patients. Visfatin expression
correlates with the viral load, and high visfatin expression
appears to be associated with the dominance of CXCR4-
using HIV in the plasma. We show that visfatin is capable
of selectively reducing the infectivity of CCR5-using
clones in primary cells (macrophages, resting PBMC) in
vitro, while at the same time remaining indifferent to or
even favouring infection by CXCR4-using virus. As such,
visfatin may play an important contributing role in the
development of the HIV coreceptor switch by mounting a
selective pressure against CCR5-using and in favour of
CXCR4-using viruses.
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